Article Information
History
- August 23, 2020.
Article Versions
- Version 1 (July 6, 2020 - 10:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Reed B. Hogan II, MDa,*,
- Reed B. Hogan III, MDa,
- Tim Cannon, MDb,
- Maria Rappai, MDb,
- John Studdard, MDb,
- Doug Paul, PharmD, PhDc and
- Thomas P. Dooley, PhDd,**
- aGI Associates, Flowood, Mississippi
- bJackson Pulmonary Associates PA, Jackson, Mississippi
- cMedical Marketing Economics (MME) and University of Mississippi, Oxford, Mississippi
- dTrends in Pharma Development LLC, Pinson, Alabama
- ↵*Corresponding Author for general correspondence Reed B. Hogan II MD, GI Associates, 2510 Lakeland Dr. Flowood, MS 39232, 601.355.1234, Reed.Hogan{at}gi.md
- ↵**Corresponding Author for manuscript submission and revision, Thomas P. Dooley, PhD, Trends in Pharma Development LLC, 7100 Cabin Lane, Pinson, Alabama 35126, 205.222.6145, Tom{at}TomDooley.org
Posted August 23, 2020.
Dual-Histamine Receptor Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients
